Effects of Tegafur, Gimeracil and Oteracil Potassium Capsules Combined with Calf Spleen Extractive Injection on Serum VEGF and MMP-9 in Patients with Advanced Gastric Cancer

Overview

Journal Am J Transl Res

Specialty General Medicine

Date 2022 Dec 12

PMID 36505301

Authors

Yan Zhang

Qiang Zhong

Xiaochun Luo

Wei Zhang

Affiliations

Soon will be listed here.

Abstract

Objective: To explore the effects of Tegafur, Gimeracil and Oteracil Potassium Capsules (TGOPC) combined with Calf Spleen Extractive Injection (CSEI) on vascular endothelial growth factor (VEGF) and matrix metalloproteinase-9 (MMP-9) in patients with advanced gastric cancer.

Methods: A retrospective analysis was conducted on data of 118 patients with advanced gastric cancer treated in Anyang Tumor Hospital from January 2016 to September 2018. The patients were divided into two groups according to treatment modalities, with control group receiving Oxaliplatin and TGOPC and observation group receiving Oxaliplatin, TGOPC and CSEI. Clinical efficacy, changes of serum VEGF and MMP-9 before and after chemotherapy, survival rate and incidence of adverse reactions were compared between the two groups.

Results: The number of responded patients was 36 (61.02%) in the observation group and was 18 (30.51%) in the control group (<0.05). The levels of serum VEGF and MMP-9, and incidence of nausea and vomiting in the observation group were lower than those in the control group (<0.05). The 1-year and 2-year survival rates in the observation group were higher than those in the control group (<0.05).

Conclusion: The use of CSEI on the basis of Oxaliplatin combined with TGOPC chemotherapy for the treatment of advanced gastric cancer could further improve the clinical efficacy and survival rate, and reduce the incidence of adverse reactions.

References

Hecht J, Bang Y, Qin S, Chung H, Xu J, Park J . Lapatinib in Combination With Capecitabine Plus Oxaliplatin in Human Epidermal Growth Factor Receptor 2-Positive Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma: TRIO-013/LOGiC--A Randomized Phase III Trial. J Clin Oncol. 2015; 34(5):443-51. DOI: 10.1200/JCO.2015.62.6598. View

Li J, Qin S, Xu J, Xiong J, Wu C, Bai Y . Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction. J Clin Oncol. 2016; 34(13):1448-54. DOI: 10.1200/JCO.2015.63.5995. View

Schachter J, Ribas A, Long G, Arance A, Grob J, Mortier L . Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006). Lancet. 2017; 390(10105):1853-1862. DOI: 10.1016/S0140-6736(17)31601-X. View

Tap W, Papai Z, Van Tine B, Attia S, Ganjoo K, Jones R . Doxorubicin plus evofosfamide versus doxorubicin alone in locally advanced, unresectable or metastatic soft-tissue sarcoma (TH CR-406/SARC021): an international, multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2017; 18(8):1089-1103. PMC: 7771354. DOI: 10.1016/S1470-2045(17)30381-9. View

Pernot S, Voron T, Perkins G, Lagorce-Pages C, Berger A, Taieb J . Signet-ring cell carcinoma of the stomach: Impact on prognosis and specific therapeutic challenge. World J Gastroenterol. 2015; 21(40):11428-38. PMC: 4616218. DOI: 10.3748/wjg.v21.i40.11428. View

Yamada Y, Higuchi K, Nishikawa K, Gotoh M, Fuse N, Sugimoto N . Phase III study comparing oxaliplatin plus S-1 with cisplatin plus S-1 in chemotherapy-naïve patients with advanced gastric cancer. Ann Oncol. 2014; 26(1):141-148. DOI: 10.1093/annonc/mdu472. View

Webb A, Gao B, Goldsmith Z, Irvine A, Saleh N, Lee R . Inhibition of MMP-2 and MMP-9 decreases cellular migration, and angiogenesis in in vitro models of retinoblastoma. BMC Cancer. 2017; 17(1):434. PMC: 5477686. DOI: 10.1186/s12885-017-3418-y. View

Kang Y, Boku N, Satoh T, Ryu M, Chao Y, Kato K . Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017; 390(10111):2461-2471. DOI: 10.1016/S0140-6736(17)31827-5. View

Jia D, Lu W, Wang C, Sun S, Cai G, Li Y . Investigation on Immunomodulatory Activity of Calf Spleen Extractive Injection in Cyclophosphamide-induced Immunosuppressed Mice and Underlying Mechanisms. Scand J Immunol. 2016; 84(1):20-7. DOI: 10.1111/sji.12442. View

10.

Wang J, Guo C, Gong X, Ao F, Huang Y, Huang L . The impacts of genetic polymorphisms in genes of base excision repair pathway on the efficacy and acute toxicities of (chemo)radiotherapy in patients with nasopharyngeal carcinoma. Oncotarget. 2017; 8(45):78633-78641. PMC: 5667987. DOI: 10.18632/oncotarget.20203. View

11.

Das M . Neoadjuvant chemotherapy: survival benefit in gastric cancer. Lancet Oncol. 2017; 18(6):e307. DOI: 10.1016/S1470-2045(17)30321-2. View

12.

Abilez O, Tzatzalos E, Yang H, Zhao M, Jung G, Zollner A . Passive Stretch Induces Structural and Functional Maturation of Engineered Heart Muscle as Predicted by Computational Modeling. Stem Cells. 2017; 36(2):265-277. PMC: 5785460. DOI: 10.1002/stem.2732. View

13.

Kato T, Seto T, Nishio M, Goto K, Yamamoto N, Okamoto I . Erlotinib Plus Bevacizumab Phase ll Study in Patients with Advanced Non-small-Cell Lung Cancer (JO25567): Updated Safety Results. Drug Saf. 2017; 41(2):229-237. PMC: 5808045. DOI: 10.1007/s40264-017-0596-0. View

14.

Alley E, Lopez J, Santoro A, Morosky A, Saraf S, Piperdi B . Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial. Lancet Oncol. 2017; 18(5):623-630. DOI: 10.1016/S1470-2045(17)30169-9. View

15.

Doi T, Shitara K, Naito Y, Shimomura A, Fujiwara Y, Yonemori K . Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody-drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study. Lancet Oncol. 2017; 18(11):1512-1522. DOI: 10.1016/S1470-2045(17)30604-6. View

16.

Han K, Chang J, Lee H, Azar D . Proangiogenic Interactions of Vascular Endothelial MMP14 With VEGF Receptor 1 in VEGFA-Mediated Corneal Angiogenesis. Invest Ophthalmol Vis Sci. 2016; 57(7):3313-22. PMC: 5993529. DOI: 10.1167/iovs.16-19420. View

17.

Stone M, Martyn L, Weaver C . Potassium Intake, Bioavailability, Hypertension, and Glucose Control. Nutrients. 2016; 8(7). PMC: 4963920. DOI: 10.3390/nu8070444. View

18.

Gomez Casanova N, Siller Ruiz M, Munoz Bellido J . Mechanisms of resistance to daptomycin in Staphylococcus aureus. Rev Esp Quimioter. 2017; 30(6):391-396. View

19.

Jia D, Lu W, Zhang X, Cai G, Teng L, Wang X . Calf Spleen Extractive Injection (CSEI), a small peptides enriched extraction, induces human hepatocellular carcinoma cell apoptosis via ROS/MAPKs dependent mitochondrial pathway. J Pharmacol Sci. 2017; 132(2):122-130. DOI: 10.1016/j.jphs.2016.08.006. View

20.

Masuishi T, Kadowaki S, Kondo M, Komori A, Sugiyama K, Mitani S . FOLFOX as First-line Therapy for Gastric Cancer with Severe Peritoneal Metastasis. Anticancer Res. 2017; 37(12):7037-7042. DOI: 10.21873/anticanres.12174. View